EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.391
https://www.valueinhealthjournal.com/article/S1098-3015(24)00506-0/fulltext
Title :
EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00506-0&doi=10.1016/j.jval.2024.03.391
First page :
Section Title :
Open access? :
No
Section Order :
11739